Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK
(2024)
Journal Article
Dixon, G., Hague, S., Mulholland, S., Adamali, H., Khin, A. M. N., Thould, H., Connon, R., Minnis, P., Murtagh, E., Khan, F., Toor, S., Lawrence, A., Naqvi, M., West, A., Coker, R. K., Ward, K., Yazbeck, L., Hart, S., Garfoot, T., Newman, K., …Barratt, S. L. (2024). Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK. ERJ Open Research, 10(1), Article 00529-2023. https://doi.org/10.1183/23120541.00529-2023
Background Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service in Scotland in... Read More about Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK.